This study provides a comprehensive analysis of the economic burdens of Parkinson's disease (PD) in the U.S. (2017) and projections for the next two decades. Using multiple data sources, including claims data, surveys, and census projections, the study estimated a 2017 U.S. prevalence of approximately one million diagnosed PD cases and a total economic burden of $51.9 billion. This included $25.4 billion in direct medical costs and $26.5 billion in indirect and non-medical costs. The study projects a prevalence exceeding 1.6 million and a total economic burden surpassing $79 billion by 2037. Interventions to reduce PD incidence, delay progression, and alleviate symptoms could substantially reduce the future economic burden.

Wenya Yang, Jamie L. Hamilton, Catherine Kopil, James C. Beck, Caroline M. Tanner, Roger L. Albin, E. Ray Dorsey, Nabila Dahodwala, Inna Cintina, Paul Hogan, Ted Thompson